There is one clinical trial.
A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of these patients continue to have considerable respiratory symptoms or persistent hypoxemia. The CT abnormalities in these patients are often a combination of ground-glass opacities and patchy multifocal consolidation consistent with a pattern of OP. In several patients, these radiologic abnormalities persist. As with other forms of OP, patients with post-COVID OP or post COVID diffuse lung disease (PC-DLD) may benefit from treatment with oral glucocorticoids. The ideal dose of glucocorticoids for treating PC-DLD is unknown. In this study, we aim to compare the efficacy and safety of a medium dose and a low dose of prednisolone (as the initial dose) for the treatment of post-COVID. diffuse lung disease.
Description: Complete response is defined as complete disappearance or ≥90% reduction in the lung parenchymal abnormalities on a high-resolution CT scanMeasure: Proportion of subjects with a complete radiologic response Time: 6 weeks
Description: Complete response is defined as complete disappearance or ≥90% reduction in the lung parenchymal abnormalities on a high-resolution CT scan. Good response is defined as ≥50% but less than 90% reduction in the lung parenchymal abnormalities on a high-resolution CT scan.Measure: Proportion of subjects with a complete or good response radiologic response Time: 6 weeks
Description: Complete or good radiologic resolution along with no oxygen desturation on exercise testingMeasure: Proportion of subjects with a good composite response Time: 6 weeks
Description: Forced vital capacity will be measured using spirometry. The predicted value will be calculated based on standard reference equations.Measure: Forced vital capacity as a percentage of the predicted Time: 6 weeks
Description: The change in resting oxygen saturation (measured by pulse oximetry) from the day of randomization to 6 weeksMeasure: Change in resting oxygen saturation Time: 6 weeks
Description: Oxygen desaturation will be defined as a fall in oxygen saturation by 4% or more on exercise testing (by one-minute sit-to-stand test and six-minute walk test)Measure: Proportion of subjects with oxygen desaturation on exercise testing Time: 6 weeks
Description: The change in dyspnea score assessed using the modified Medical Research Council (mMRC) scale from the day of randomization to 6 weeksMeasure: Change in dyspnea score Time: 6 weeks
Description: Severity of dyspnea assessed using the FACIT-Dyspnea scaleMeasure: Severity of dyspnea Time: 6 weeks
Description: Respiratory health status assessed using the King's Brief ILD questionnaireMeasure: Respiratory health status Time: 6 weeks
Description: Health-related quality of life assessed using Short Form-36 questionnaireMeasure: Health-related quality of life Time: 6 weeks
Description: The adverse effects of treatment (acne, weight gain, hyperglycemia, hypertension, abdominal pain, dyspepsia, Cushingoid facies, skin thinning and bruising, mood changes, muscular weakness and any other adverse effects related to prednisolone)Measure: Adverse effects of prednisolone Time: 6 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports